Novo Nordisk will only be able to supply limited quantities of certain Wegovy dose strengths to U.S. retail pharmacies given the surge in demand for the product.
is cutting U.S. supply on certain dose strengths of its highly sought-after weight loss drug Wegovy due to strong demand.
"Prescribing trends continue to increase at a substantial rate and indicate that demand for Wegovy in the U.S. will exceed our current supply capacity," Novo Nordisk said. Both drugs, which faced supply constraints due to unprecedented product demand, were temporarily listed on the Food and Drug Administration 's list of drug shortages last year. Both drugs are listed as "currently available" on the FDA's site.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Novo Nordisk limits distribution of low doses of Wegovy in U.S.Novo Nordisk is holding back low doses of Wegovy, its recently approved obesity medication, in the U.S. to conserve supplies for patients already using the drug, the company said Thursday.
Les mer »
Novo Nordisk rivals see room to compete in $100 billion weight-loss drug marketThe enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said.
Les mer »
Oral Weight-Loss Drug Will Have Similar Efficacy as WegovyNovo Nordisk expects the oral version of its semaglutide drug to treat obesity to have similar efficacy as its Wegovy injection, with data from a late-stage clinical trial due before the end of June
Les mer »
Wegovy U.S. Supply Shortage Strikes AgainNovo Nordisk's problems keeping up US supply of Wegovy for weight-loss is back after a brief hiatus, as the company says starter doses will again be in short supply through September.
Les mer »
Wegovy US Supply Shortage Strikes AgainNovo Nordisk's problem with keeping up the US supply of semaglutide for weight loss (Wegovy) is back after a brief hiatus, as the company says starter doses will again be in short supply through September.
Les mer »
Room to Compete in $100 Billion Weight-Loss Drug MarketThe enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the US, industry executives and analysts said.
Les mer »